The drug evaluation and classification program we are currently running is the same program we were running with the previous Bill C-16, and before that with the first Bill C-32.
The $4.6 million that was announced as being cut wasn't really cut, because we never had it. A total of $7 million over three years was tied to Bill C-16. With the first year for all intents and purposes lapsing, it became $4.6 million while the bill itself was being debated. With the call for an election the $4.6 million was parked, showing that we still had the money, but we never had access to it.
Our current funding is through Canada's drug strategy. We receive an ongoing $2.1 million a year through the drug strategy for training. But right now there are no additional funds.